Synribo

Those who have a type of cancer called chronic myeloid leukemia (CML) may receive Synribo after at least two other medications have been tried. This prescription chemotherapy drug is used when the cancer has become worse or when the prior treatment could not be tolerated. It is given as an injection just under the skin. Side effects include diarrhea, fatigue, and anemia.

 

What Is Synribo?

Synribo™ (omacetaxine mepesuccinate) is a prescription medication approved for the treatment of chronic myeloid leukemia (also known as chronic myelogenous leukemia, or simply CML), a type of cancer of the blood and bone marrow.
 
Synribo is used in people who have already received at least two medications in a class of drugs known as tyrosine kinase inhibitors. It is recommended when the leukemia has progressed, despite the other treatment, or when the treatment could not be tolerated.
 
(Click Synribo Uses for more information on this topic, including possible off-label uses.)
 

Who Makes This Medication?

Synribo is manufactured by Teva Pharmaceuticals, USA, Inc.
 

Clinical Effects

Synribo was studied in clinical trials that included people with CML who had previously been treated with at least two tyrosine kinase inhibitors but did not tolerate the medications or did not adequately respond to them. In these studies, 18.4 percent of people with chronic-phase CML, on average, had a major cytogenetic response, meaning 35 percent or less of cells tested positive for the Philadelphia chromosome (a genetic abnormality found in most people with CML).
 
It took a median of 3.5 months for this reduction in leukemia cells to occur (the median is the middle number, meaning half of the people responded within 3.5 months, while the other half took longer than 3.5 months). The reduction in leukemia cells lasted a median of 12.5 months.
 
5 Quick Tricks for Overcoming Nicotine Cravings

Synribo Chemotherapy Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.